Skip to content
MarketScale
‹ Back to IndustriesSciences

Hyundai Motors Acquires Boston Dynamics: How Can Robotics Scale Car Manufacturing?

Hyundai Motors has acquired Boston Dynamics for over $1 billion, signaling a significant move towards increased use of robotics in car manufacturing. The investment is seen as a step towards integrating advanced automation and enhancing research and development for new vehicles. Experts believe combining robotics with human efforts could lead to improved manufacturing efficiency.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Daniel Litwin · AutomationAutomotiveAutomotive ManufacturingBoston Dynamics
Share
Hyundai Motors Acquires Boston Dynamics: How Can Robotics Scale Car Manufacturing?

Key takeaways

01

Hyundai Motors invested more than $1 billion in acquiring Boston Dynamics to advance robotics in automotive manufacturing.

02

Experts believe the integration of robotics is aimed at enhancing research and development efforts rather than immediate large-scale changes.

03

A symbiotic relationship between humans and robotic systems could lead to significant efficiency gains in manufacturing.

Get featured

Want to get featured in MarketScale Sciences?

Create a free MarketScale workspace and get your company's expertise featured across our Sciences coverage. No credit card, no demo required.

Start free

Automotive industry giant Hyundai Motors made waves recently, acquiring noted robotics lab Boston Dynamics for more than $1 billion. That’s a hefty investment – but what does it really represent?

To find out, Voice of B2B Daniel Litwin sat down with Konstantin Maslennikov, CEO and Founder of HereYouGo, which is working to empower anyone to rent part of a fleet of autonomous vehicles as we collectively move toward a self-driving future.

Even though Hyundai’s aggressive move represents a big step toward increased automation, Maslennikov said the process might be more glacier than avalanche.

“You cannot change everything in one day,” he said. “I think it’s more for research and development purposes, mostly. … Maybe for new vehicles.”

The duo explored where Hyundai might get the most out of its investment in Boston Dynamics, how robotic solutions are getting smarter and preparing to scale up, the role of automation in self-driving vehicle manufacturing at scale, and more.

While many companies are working toward that future, it’s still easier to use humans than artificial intelligence in some applications.

“It’s going to be some kind of symbiosis,” Maslennikov said. “Because, if people work with computers, the efficiency just grows very fast. … But we are not there yet, especially with AI enablement. Like, robots making robots? Robots making self-driving cars? We are not there yet.”

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Sciences starts with a company putting its lab directors, applications scientists, and field specialists on the record. Buyers are already reading this topic. The only question is whose experts they find.

Lab and research buyers verify before they trial, and your scientists give them something credible to verify against.

Get your team featuredSee how it works15 minutes, straight to a calendar.

About the author

Daniel Litwin
Daniel LitwinEditor, B2B Media, MarketScale

Daniel Litwin is a journalist of multiple disciplines focused on finding and telling engaging stories for B2B communities. He has interviewed executives from Fortune 500 companies including Honeywell, Microsoft, John Deere, and Chipotle, and leads editorial direction at MarketScale. Litwin hosts weekly shows and podcasts while helping develop new content approaches across the MarketScale platform. He holds a B.J. in Radio/Television Reporting/Anchoring and a B.A. in Spanish from the University of Missouri-Columbia.

Follow Sciences Insights

Get new expert content in your inbox.

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Sciences expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your lab directors, applications scientists, and field specialists into the articles, video, and social content Sciences buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Sciences Insights

Pharma supplier diversification means little if every supplier uses the same airport

Pharma supplier diversification means little if every supplier uses the same airport

Biocair's Patrick Wohl argues in Pharmaceutical Commerce that life sciences firms must map airports, sea lanes, customs gateways and carriers alongside suppliers. Suppliers spread across countries can still share one air hub. The fix he describes is pre-qualified alternate routes and continuous review, with clinical trial shipments and cold-chain medicines the first cargo exposed when a corridor closes.

  • 01A supplier base spread across several countries can still be a single point of failure if every shipment routes through one airport hub or corridor; the sharper question for a logistics provider is which hubs each qualified lane actually depends on.
  • 02Gartner data cited by MD+DI gives a benchmark: 42% of procurement leaders rank supply disruption as their organization's top risk, with geopolitical issues including tariffs and regulatory changes ranking third.
  • 03A route map ages fast. Pharmaceutical Commerce published the mapping argument on July 24 and was reporting fresh Red Sea and Iran-related freight risk for pharma lanes by Aug. 10, which is the case for treating mapping as a recurring review rather than a project.

Sep 17, 2026

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Lilly Invest $750 Million to Increase U.S.-Manufactured Medicine Supply

Resilience and Eli Lilly are investing $750 million to expand KwikPen injectable device production at Resilience's Cincinnati-region manufacturing facility, expected to create 400 high-skilled jobs and reach full operations by early 2027. The partnership builds on their collaboration since 2023, which has already produced over 150 million doses of Lilly medications for the U.S. market.

  • 01$750 million investment to expand Resilience's Ohio manufacturing capacity for Eli Lilly's KwikPen injectable device production
  • 02400 new high-skilled jobs expected in Cincinnati region, with full operations by early 2027
  • 03Partnership has already produced over 150 million doses of Lilly medications for the U.S. market since 2023

Sep 14, 2026

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS ran an AI controller on a distillation column for 35 days and cut steam use 40%

ENEOS Materials and Yokogawa ran an autonomous AI controller on a butadiene distillation column for 35 days and cut steam use 40%. It’s a real operations proof point. It also puts integration and governance gaps front and center.

  • 01A 35-day closed-loop run is a stronger autonomy proof point than a demo, it forces plants to prove handover, fallback, and KPIs over real feed and operating swings.
  • 02Steam reduction claims are compelling, but procurement and ops teams should pin vendors to baselines, operating envelopes, and how off-spec avoidance is measured.
  • 03Agentic AI is showing up as “work management” and “shift checklist” agents before it replaces control engineers, which shifts requirements toward clean, permissioned data access.

Sep 13, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

Daniel Litwin
Daniel Litwin

Voice of B2B at MarketScale

MarketScale

Daniel Litwin is a communications specialist focused on B2B industries, providing insights and commentary across a range of sectors. He works with MarketScale to deliver valuable insights in engineering, construction, and technology fields.

KM
Konstantin Maslennikov

CEO and Founder

HereYouGo

Konstantin Maslennikov is the CEO and Founder of HereYouGo, a company focused on advancing autonomous vehicle technology and enabling rental models for fleet sharing. He is a thought leader in self-driving technology and automation.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512